To engage the medical and investment communities in conversation around “antibiotic resistance crisis”. Helperby Therapeutics is a biopharmaceutical company that currently develops technologies called ‘antibiotic resistance breakers’, that combine with existing antibiotic treatments to future-proof their potency.
Following a full stakeholder audit and community planning, ROAD facilitated and interpreted an on and offline programme to engage the medical, research, and investment communities in conversation around the global “antibiotic resistance crisis”, and Helperby’s unique solution in combining its technology with existing antibiotic treatment to future-proof their potency.
ROAD provided targeted social media activity around an influential industry conference.
Activity resulted in a 39% increase in the number of followers, with 79% of new followers identifying as Helperby’s target audience. During the conference, Helperby content was seen 22,514 times by conference delegates, more than twice per delegate.
• New corporate positioning
• A defined strategy for social and digital media assets
• Key industry stakeholder engagement, connecting with business stakeholders around key conferences
Contact Paul Jarman (Managing Director)
+ 44 (0)208 995 5832
